Related Experiment Videos
[Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy]
1Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
Purpose:
To evaluate efficacy of dexrazoxane (Cardioxane) in amelioration of chemotherapy induced cardiotoxicity.
Design:
The most important experimental and clinical studies have been reviewed.
Results:
Dexrazoxane has been shown to reduce anthracycline-induced cardiotoxicity. The drug is thought to reduce cardiac toxicity by binding to free and bound iron, thus reducing the formation of anthracycline-iron complexes and the generation of free radicals which are toxic to cardiac tissue. The majority of clinical studies has been performed in patients with metastatic breast cancer. It has been shown that dexrazoxane: 1) significantly reduces the overall incidence of cardiac events, irrespective of pre-existing cardiac risk factors; 2) does not seem to affect anthracycline activity; 3) does not increase the incidence of chemotherapy induced non-cardiac toxic effects; 4) reduces cardiac toxicity in pediatric patients given anthracyclines; 5) is cost-effective.
Conclusions:
Dexrazoxane is a valuable drug in amelioration of chemotherapy induced cardiotoxicity, both in adult and pediatric patients. Wether it offers protection against late-onset cardiac toxicity in this latter group of patients, remains to be demonstrated. Dexrazoxane should be always used, preferably from the onset of chemotherapy, when it is believed that cumulative doses of doxorubicin > or = 300 mg/m2 or of epirubicin > or = 480 mg/m2 will be reached.
Insights
Dexrazoxane significantly reduces chemotherapy-induced heart damage in adult and pediatric patients. This cardioprotective drug is cost-effective and does not impede cancer treatment efficacy.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Context:
- Chemotherapy, particularly anthracyclines, can cause significant cardiotoxicity.
- Cardiotoxicity poses a serious risk to patients undergoing cancer treatment.
- Preventive strategies are crucial for managing treatment-related adverse events.
Purpose:
- To evaluate the efficacy of dexrazoxane (Cardioxane) in preventing and mitigating chemotherapy-induced cardiotoxicity.
- To review experimental and clinical evidence supporting dexrazoxane's cardioprotective role.
Summary:
- Dexrazoxane effectively reduces anthracycline-induced cardiotoxicity by chelating iron and preventing free radical formation.
- Clinical studies demonstrate dexrazoxane's ability to lower the incidence of cardiac events in metastatic breast cancer patients.
- The drug shows efficacy in both adult and pediatric populations, without compromising anti-cancer treatment or increasing non-cardiac toxicities.
Impact:
- Dexrazoxane is a valuable cardioprotective agent for adult and pediatric patients receiving anthracycline chemotherapy.
- Its use is recommended when cumulative doses of doxorubicin or epirubicin reach specific thresholds.
- Further research is needed to confirm its efficacy against late-onset cardiac toxicity.